Genky DrugStores Co., Ltd. (TYO:9267)
Japan · Delayed Price · Currency is JPY 4,670.00
-30.00 (-0.64%)
Feb 13, 2026, 3:30 PM JST
Genky DrugStores Income Statement
Financials in millions JPY. Fiscal year is July - June.
Millions JPY. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 20, 2025 | Jun '25 Jun 20, 2025 | Jun '24 Jun 20, 2024 | Jun '23 Jun 20, 2023 | Jun '22 Jun 20, 2022 | Jun '21 Jun 20, 2021 |
| 211,289 | 200,786 | 184,860 | 169,059 | 154,639 | 142,376 | |
Revenue Growth (YoY) | 10.25% | 8.62% | 9.35% | 9.32% | 8.61% | 15.19% |
Cost of Revenue | 168,030 | 159,896 | 147,239 | 134,505 | 123,685 | 112,087 |
Gross Profit | 43,259 | 40,890 | 37,621 | 34,554 | 30,954 | 30,289 |
Selling, General & Admin | 26,725 | 25,433 | 23,518 | 23,194 | 21,000 | 19,913 |
Other Operating Expenses | - | - | - | - | - | 339 |
Operating Expenses | 32,523 | 31,231 | 28,605 | 27,844 | 25,279 | 23,994 |
Operating Income | 10,736 | 9,659 | 9,016 | 6,710 | 5,675 | 6,295 |
Interest Expense | -236 | -216 | -103 | -70 | -59 | -55 |
Interest & Investment Income | 15 | 10 | 7 | 8 | 9 | 9 |
Other Non Operating Income (Expenses) | 507 | 445 | 347 | 430 | 437 | 352 |
EBT Excluding Unusual Items | 11,022 | 9,898 | 9,267 | 7,078 | 6,062 | 6,601 |
Gain (Loss) on Sale of Investments | - | - | - | - | 25 | - |
Gain (Loss) on Sale of Assets | -1 | 5 | -14 | 10 | 1 | - |
Asset Writedown | -3 | -3 | -286 | -386 | -9 | -56 |
Other Unusual Items | 2 | 2 | -165 | 1 | 4 | 117 |
Pretax Income | 11,020 | 9,902 | 8,802 | 6,703 | 6,083 | 6,662 |
Income Tax Expense | 3,202 | 2,836 | 2,478 | 1,939 | 1,663 | 1,831 |
Net Income | 7,818 | 7,066 | 6,324 | 4,764 | 4,420 | 4,831 |
Net Income to Common | 7,818 | 7,066 | 6,324 | 4,764 | 4,420 | 4,831 |
Net Income Growth | 20.18% | 11.73% | 32.75% | 7.78% | -8.51% | 75.35% |
Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 30 |
Shares Change (YoY) | 0.13% | 0.13% | 0.09% | -0.02% | 0.03% | 0.10% |
EPS (Basic) | 257.06 | 232.49 | 208.18 | 156.89 | 145.59 | 159.15 |
EPS (Diluted) | 256.35 | 232.04 | 207.94 | 156.79 | 145.44 | 159.01 |
EPS Growth | 19.95% | 11.59% | 32.62% | 7.81% | -8.54% | 75.20% |
Free Cash Flow | -3,742 | -2,495 | 2,978 | -1,118 | -4,388 | 3,263 |
Free Cash Flow Per Share | -122.77 | -81.92 | 97.91 | -36.79 | -144.36 | 107.39 |
Dividend Per Share | 13.000 | 13.000 | 12.500 | 12.500 | 12.500 | 12.500 |
Dividend Growth | 1.96% | 4.00% | - | - | - | - |
Gross Margin | - | 20.36% | 20.35% | 20.44% | 20.02% | 21.27% |
Operating Margin | 5.08% | 4.81% | 4.88% | 3.97% | 3.67% | 4.42% |
Profit Margin | 3.70% | 3.52% | 3.42% | 2.82% | 2.86% | 3.39% |
Free Cash Flow Margin | -1.77% | -1.24% | 1.61% | -0.66% | -2.84% | 2.29% |
EBITDA | 17,430 | 15,951 | 14,582 | 11,665 | 10,267 | 10,353 |
EBITDA Margin | - | 7.94% | 7.89% | 6.90% | 6.64% | 7.27% |
D&A For EBITDA | 6,694 | 6,292 | 5,566 | 4,955 | 4,592 | 4,058 |
EBIT | 10,736 | 9,659 | 9,016 | 6,710 | 5,675 | 6,295 |
EBIT Margin | - | 4.81% | 4.88% | 3.97% | 3.67% | 4.42% |
Effective Tax Rate | - | 28.64% | 28.15% | 28.93% | 27.34% | 27.48% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.